

Format for ANSWERING REVIEWERS



January 14, 2015

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 15097-review.docx).

Title: Metformin and cancer: Technical and clinical implications for FDG-PET imaging

Authors: Selene Capitanio, Cecilia Marini, Gianmario Sambuceti, Silvia Morbelli

Name of Journal: *World Journal of Radiology*

ESPS Manuscript NO: 15097

Herewith please find enclosed our replies to your comment, as well as the corrections made to the text. Again, we used the following code, for your convenience:

Underlined text: Your point

Plain text: our response

Highlighted text: correction in the manuscript

- 1) Please sign the conflict-of-interest statement in your own handwriting. And this file is not the uniform format. Thank you!

Conflict-of-interest statement has been added in our own handwriting and sent as PDF format.

- 2) Author contributions: XXX (family name should be put first in full, followed by middle names and first name in abbreviation with first letter in capital) designed research; XXX performed research; XXX contributed new reagents or analytic tools; XXX analyzed data; XXX wrote the paper. An author may list more than one contribution, and more than one author may have contributed to the same aspect.

Author contributions have been added as follows:

Author contributions: Morbelli S designed the study; Capitanio S performed literature search and draft the manuscript; Marini C, Sambuceti S and Morbelli S made critical revisions related to important intellectual content of the manuscript; Morbelli S have given final approval of the version of the article to be published. All authors read and approved the final manuscript.

- 3) INTRODUCTION Please add the Heading 1 like this for your manuscript.

The text has been subdivided in 5 paragraphs and headings have been added.

INTRODUCTION

METFORMIN AND CANCER

METFORMIN AND FDG-PET IMAGING: TECHNICAL AND CLINICAL IMPLICATIONS

FUTURE DIRECTIONS

CONCLUSIONS

- 4) Reference format: The format should be like this. Please revise.

Reference format has been revised according to BPG's Revision Policies, we added the corresponding

PMID number and DOI. Furthermore we added 3 references (number 6, 11 and 12) in order to reach the number of references reported in BPG's Revision Policies for Editorial. Accordingly, following references have been also modified.

Ref 6. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. *Cancer Discov* 2012; 2: 778-790 [PMID: 22926251 DOI 10.1158/2159-8290.

Ref 11. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: A meta-analysis. *Cancer Epidemiol* 2013; 37: 207–218 [PMID: 23352629 DOI: 10.1016/j.canep.2012.12.009]

Ref 12. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. *PLoS One* 2012; 7: e33411 [PMID: 22448244 DOI:10.1371/journal.pone.0033411]

5) Ref 24 and 26 are same, please revise. Thank you!

We corrected ref number 26 that was already mentioned as ref 24.

Reviewer 575396

1) Please, review English language, particularly the second page of the manuscript, line 28: inhibit directly inhibits.

We correct the second page of the manuscript, line 28 as follows:

Another important role of metformin that could be involved in antineoplastic activity and thus can interfere with FDG uptake, is its capability to directly and selectively inhibit ~~directly inhibits~~ the enzymatic function of hexokinase (HK) I and II as demonstrated by Marini et al.^[27].

Reviewer 391150

1) Dear authors, well written manuscript that need some correction in grammar and style.

Thank you for your help in improving the quality of the manuscript. To this purpose we make some changes in the text in order to improve English language, particularly the grammar and the style. We highlighted all the changes made in the text and we crossed out the sentences that have not to be considered. Finally, we added “manuscript tracking” notes in the second page of the manuscript, according to the writing requirements of editorial.

We are sorry for the delay.

We hope to have made all the changes needed.

Looking forward for hearing from you soon

Regards

Silvia Morbelli

Address for Correspondence:

Silvia Morbelli ID (02793276)

Nuclear Medicine Physician c/o Nuclear Medicine Unit , University of Genoa, IRCCS San Martino - National Institute for Cancer, L.go R. Benzi 10, 16132-Genova, Italy.

Phone: +39 010 555 2025

Fax: +39 010 555 6911

silviadaniela.morbelli@hsanmartino.it

